CClinicalTrials.gg
CompletedNCT06146348Updated Apr 21, 2026

Deimplementing CXR After CVC (DRAUP) in the ICU

An interventional study of adapted DRAUP strategy bundle in Implementation Science and Behavior and Behavior Mechanisms, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study proposes adapting and testing an innovative, behavioral theory-driven deimplementation program called DRAUP in two intensive care units for proof of concept and support that the program can help providers and hospital organizations address context determinants of deimplementation. Study data will be used to optimize the intervention for a subsequent larger trials.

Read the detailed description

There are millions of critically ill patients annually who require imaging confirmation after central venous catheter insertion. Emerging literature demonstrates that ultrasound is a faster alternative to historical chest xray, thus serving as the ideal confirmation for catheter use. When able to confirm catheter position, ultrasound decreases the number of unnecessary chest radiographs, cumulative resources (technologist, radiologist, equipment), and patient care delays. However, providers are not adopting this practice. Previously, we developed and initiated a successful evidence-based deimplementation program for ultrasound in lieu of chest xray called DRAUP in the Emergency Department. We now move to adapt the deimplementation bundle in the new environment of the Intensive Care Unit (ICU) with hopeful continued success.

In experiment 1, qualitative analysis will be employ a systematic approach to DRAUP component refinement dosed to the unique context of the Intensive Care Unit and implementation outcomes as well as cost will be evaluated. In experiment 3, mixed methods will be used to evaluate the mechanism of impact of the refined program in the new environment.

02

Conditions studied

  • Implementation Science
  • Behavior and Behavior Mechanisms

Browse trials for

03

In context

Behavior

371 studies on the registry are indexed under Behavior; 158 are open to participants now.

This study's enrollment of 101 is below the median of 120 across 295 interventional studies indexed under Behavior.

Browse Behavior studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,765 studies on the registry; 271 are open to participants now.

Of its 324 completed or terminated interventional studies of FDA-regulated products, 212 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

-Measure the effectiveness and cost effectiveness of DRAUP on discontinuation of CXRs

Inclusion Criteria for DRAUP training:

(1) ICU faculty, fellows, senior residents (post graduate year 3) and advanced practice practitioners

  • ICU inclusion for DRAUP program:
  • Availability of ultrasound machines with archiving capability (DICOM)
  • A minimum of 100 supradiaphragmatic CVC insertions annually in adult patients (age >18)
  • Capacity to access digital archiving (PICOM)
  • Patient inclusion for DRAUP program:
  • supradiaphragmatic CVC placed
  • Patient exclusion for DRAUP program:
  • severe instability (cardiac arrest, severe shock) where CVC would be used without CXR,
  • level 1 trauma;
  • burn patients with no viable skin surface for imaging
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    CVC confirmed by DRAUP

    new mode of CVC confirmation for correct location and excluding pneumothorax

    Behavioral: adapted DRAUP strategy bundle

  • Experimental
    CVC confirmed by CXR

    traditional mode of CVC confirmation for correct location and excluding pneumothorax

    Behavioral: adapted DRAUP strategy bundle

Interventions

  • Behavioraladapted DRAUP strategy bundle

    DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.

06

What researchers measure

Primary outcomes

  1. DRAUP in

    Deadoption of CXR after US guided CVC confirmation

    Time frame: 24 months

Secondary outcomes

  1. Fidelity

    Percentage of DRAUP non-adherence

    Time frame: 24 months

07

Study locations

1 site
  • Washington University School of Medicine
    St Louis, Missouri 63108, United States
08

References and documents

Individual participant data

Plan to share: Yes — IPD sharing upon request

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06146348
Lead sponsor
Washington University School of Medicine
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Enyo Ablordeppey (Assoc Prof of Anesthesiology, Washington University School of Medicine) — Principal investigator
First posted
Nov 24, 2023
Start date
Jan 1, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Apr 21, 2026

Study contacts

Enyo Ablordeppey, MD MPH
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion